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Abstract
Without prompt identification, screening and treatment of iron deficiency (ID), patients with
heart failure (HF) will continue to struggle with poor health and higher health care
utilization, impacting patient-centered and health care outcomes. This is particularly
concerning in rural areas with limited access to services, especially for those who cannot
easily leave the home for medical care. Currently, comorbid ID remains under-detected and
under-treated yet current evidence supports treatment in patients with HF for the
improvement of symptoms. It is not known if patients with all types of HF could benefit from
oral iron in the home setting, but those patients at-risk must first be identified for screening
and treatment purposes. The aim of this quality improvement project was to retrospectively
review data to understand the impact of an algorithm to identify and to treat ID in this
population. Descriptive data points were demographics, types of HF, anemia treatment and
utilization but were not collected and analyzed for this DNP project due to a student contract
impasse. Considerations and recommendations for future projects are discussed.
Keywords: heart failure, iron deficiency, rural, quality improvement
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Identification of Iron Deficiency in Heart Failure
Chapter 1
Introduction and Background

Background
Up to 50% of patients with heart failure (HF) may suffer from iron deficiency (ID)
and can be unaware that this contributes to worsening symptoms and outcomes. Providers
also do not have a reliable evidence-based process by which to identify these at-risk patients
to ensure they receive optimal care and treatment of ID; specifically, those patients who live
in rural counties in the mid-Atlantic region with limited access to care and to services may
need enhanced oversight to reduce barriers to and gaps in care. Without prompt
identification, screening and treatment of ID, patients with HF will continue to struggle with
poor health and higher health care utilization, impacting patient-centered and health care
outcomes.
Heart failure is a common diagnosis in the elderly population with rising prevalence
and morbidity with increasing cost of care, both individually and organizationally. Heart
failure readmissions are particularly costly to health systems in the current U.S. era of valuebased payment models when hospitals can be penalized for readmissions within 30 days. It
is a complex disorder with multiple contributing factors and many specialists should be
involved in care decisions (Maddox et al., 2021).
Significance
Currently, comorbid ID remains under-detected and under-treated yet current
evidence supports treatment in patients with HF for the improvement of symptoms (Silver &
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Anker, 2021). Thus, international and U.S. cardiology organizations are focusing efforts at
improving care through guideline-directed medical therapies among which is the treatment
of ID (Maddox et al., 2021). A treatment algorithm exists for patients with ID in the
outpatient setting. However, not all HF patients are captured in that setting, including those
living at home in rural communities.
Multidisciplinary home-based programs for patients with chronic illness who live in
rural counties have been developed by large health care systems to address this at-risk
population. One innovative program has proven to be effective in reducing health care
utilization. There have been reductions in hospital admissions among targeted home-based
patients which translates to a healthier community. The ongoing challenge is to create
proactive clinical interventions to favor outcomes, and not simply follow an acute response
to HF decompensation with utilization of health care resources.
Traditionally, these home-based programs have strong institutional support. Hospitalbased clinics often collaborate with outpatient providers to identify gaps in care in this home
population and assist with treatment design utilizing evidence-based algorithms. From this
collaboration, gaps in care for patients at home with HF who may have ID can be identified.
Targeting these patients with an evidence-based process is often a clinical and
organizational priority.
Treatment
Current evidence supports the use of intravenous (IV) iron in patients with a specific
subtype of HF and ID to reduce poor outcomes (Anker et al., 2018; Jankowska et al., 2016).
Clinical trials are ongoing; it is unknown if all patients with HF will need IV iron. Yet, there
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are still unmet needs in current practice; treatment may not always be accessible to patients
who live in rural areas with limited transportation to outpatient specialty practices or to
clinics within hospitals. Furthermore, those at-risk patients may also be missing routine
follow up visits with specialty providers on a regular basis, supporting the urgency to
identify ID in patients in home-based programs. Such a program provides a critical safety
net and is well- positioned to collaborate with a hospital-based clinic to facilitate iron
administration in the home, if indicated.
The need for ID screening is high. Many patients from rural areas do not follow up
with providers on a regular basis and may miss even basic blood work that can identify
anemia. Thus, the at-risk patients with HF need to be identified, screened and treated for ID
utilizing a standardized treatment algorithm. Patients are often treated with oral iron for 8
weeks, then laboratory testing is repeated until clinical targets are achieved. Some patients
may receive IV iron; some patients could be excluded from treatment for other medical
conditions.
Quality Improvement
Iron deficiency is not a benign condition to be ignored or minimized. In general, HF
patients want to feel better, have fewer daily symptoms and stay out of the hospital.
Improvement in symptoms is one key reason to administer iron (Maddox et al., 2021). It is
not known how these rural patients with HF experience ID. There are current HF-specific
assessments available to evaluate patient symptom burden related to ID, including exercise
tolerance. Thus, utilization of a validated HF tool may be important to consider to improve
patient-centered care and prognostication which are linked to outcome metrics.
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This project will utilize Donabedian’s model of quality improvement following the
structure, process, outcome (SPO) framework. This model is explained in depth in the
literature review. There is usually strong institutional support for quality improvement, thus
a process application would be a logical next step. To assess the effect of the process to
identify, screen and treat patients with HF for ID, data need to be collected for analysis.
Therefore, the aim of this quality improvement project will be to retrospectively review data
to understand the impact of the process to identify and to treat this population. Descriptive
data points including demographics, HF types and anemia treatment will be collected.
It is not known if patients with all types of HF could benefit from oral iron in the
home setting, but those patients at-risk must first be identified for screening and treatment
purposes. The data may support the development of a best-practice alert in the electronic
health record for providers in home programs to assist in the quality care of patients with
HF, alerting the care teams for routine blood work in patients with HF. In addition,
symptom assessment related to HF and ID may not be currently collected. Thus, there may
be a gap in monitoring of patient symptom burden, supporting the use of a validated tool in
the home setting for additional metrics. Without this project, HF patients may not be
screened for ID in a coordinated, timely way and may continue with disease progression and
high health care expenditures.
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Chapter 2
Literature Review
Overview
This chapter will include: an overview of the problem, a section of definitions and
concepts, an explanation of the theoretical framework guiding this project, a review of the
search strategy in the review of the literature, a critical appraisal of the current literature and
a summary with identified gaps in the research and proposal of the current project.
Problem
Heart failure (HF) is a chronic illness with rising prevalence in the United States
(U.S.) that utilizes high healthcare resources, greatly affects morbidity and mortality, and
impacts quality of life, often later in life in persons with multiple comorbidities. In 2009,
Djousse, Driver, & Gaziano estimated 1 in every 5 adults aged 40 years will develop HF in
the future. Prevalence continues to rise over time with approximately 6 million American
adults at or above age 20 being affected according to 2015-2018 data and is higher in
women than men at or over the age of 80 years. The estimated direct cost of cardiovascular
disease increased from $103.5 billion in 1996 to 1997 to $216 billion in 2016 to 2017
(Virani et al., 2021). Comorbidities are associated with increased symptom and functional
burden, may contribute to the progression of disease and may impact prognosis. Currently,
up to 50% of patients with HF have a comorbid diagnosis of iron deficiency (ID). To
provide optimal care, clinicians must consider the treatment of this condition in addition to
utilizing the most current evidence-based therapies in HF management (Maddox et al., 2021,
von Haehling et al., 2019; Silver & Anker, 2021).
In 2013, organizational guidelines were developed to define objectives and to shape
5

the course of HF treatment utilizing the most current data. The most recent treatment
guidelines from the American College of Cardiology (ACC), American Heart Association
(AHA), and Heart Failure Society of America (HFSA) are updating this year to reflect
current evidence in HF treatments and to enhance patient-centered care; guidelines and
algorithms from 2017 are being been revised to include the most recent advances in
guideline-directed medical therapy (GDMT) from the ACC Expert Consensus Decision
Pathway (ECDP) for Optimization of Heart Failure Treatment with an updated list of pivotal
issues in HF management, including care coordination and comorbidity treatment (Bozkurt
et al., 2021; Maadox et al., 2021; Virani et al., 2021).
With underlying systemic inflammatory activation, patients with HF are at an
increased risk of developing ID, and ID is related to impaired oxidative metabolism and
decreased oxygen storage in myoglobin; additionally, the presence of ID is an independent
predictor of worse survival. Furthermore, anemia prevalence in patients with more advanced
HF is under detected and undertreated (Silver & Anker, 2021; von Haeling et al., 2019).
Screening and identifying HF patients for ID using established clinical criteria and treating
those patients with iron replacement is a current evidence-based strategy to improve patient
and health system outcomes; however, there is no current established algorithm outlining
the optimal time of screening for ID in patients with HF in the home setting. Thus, affected
symptomatic patients may miss this critical intervention, potentially impacting patient and
health system outcomes.
Definitions
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According to the universal definition by the HFSA, HF is defined as a clinical
syndrome with prior or current symptoms caused by a structural and/or functional cardiac
abnormality and corroborated by an elevated B-type NS natriuretic peptide (BNP) or
objective evidence of pulmonary or systemic congestion (Bozkurt et al., 2021). Heart failure
is a complex clinical syndrome that impairs the ability of the lower heart chamber or
ventricle to fill with or to eject blood and is a constellation of symptoms produced in
response to cardiac dysfunction; as HF advances, remodeling of the ventricles impacts the
ability of the heart to pump or fill effectively resulting in increased symptoms and worse
outcomes (Yancy et al., 2013).
Heart failure can be classified by symptoms and by the ventricular ejection fraction
(EF) which is documented as the percentage of blood pumped out of the heart during each
contraction. Heart failure is defined for this project using the New York Heart Association
(NYHA) four stages which focus on exercise capacity and symptomatic status which assists
clinicians in providing the most appropriate GDMT. The NYHA class I patients have no
symptoms at rest and can perform ordinary activities without any limitations; class II
patients have mild symptoms with somewhat limited ability to exercise with no symptoms at
rest; class III patients have moderate limitations in the ability to exercise and are
comfortable only at rest; and class IV patients have symptoms at rest and cannot do any
activities without discomfort.
A normal EF of the ventricle is > 55%. In HF, reduced EF to < 40% is defined as HF
with reduced EF(HFrEF); HF with an EF between 40% to 49% is defined as mildly reduced
EF (HFmrEF) and HF with preserved EF > 50% is shown as HFpEF (Bozkurt et al., 2021).
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Although somewhat generalizable to all HF patients, the ECDP focuses on patients with
chronic ambulatory HF with an EF of less than or equal to 40%. The ECDP reports an
association of iron deficiency to heart failure outcomes and suggests clinicians may consider
intravenous (IV) iron replacement for symptom improvement in this cohort.
Screening is utilized in a stable setting to look for an abnormality in this HF
population as it significantly impacts underlying health issues and risks of progression
(Silver & Anker, 2021). Iron deficiency in HF patients is defined by blood work obtained
through a recent complete blood count (CBC) with hemoglobin (hgb) < 13 g/dl in males and
< 12 g/dl in women. These criteria are supported by the World Health Organization. A
serum ferritin level < 100 mcg/L or ferritin level between 100-299 mcg/L with transferrin
saturation (TSat) < 20% (von Haehling et al., 2019) is also needed for diagnosis.
Patients to be enrolled in this project would receive care through a health systemsupported home program (HP) which includes a physician, advanced practice provider/nurse
practitioner (NP), a registered nurse (RN) and community health workers (CHW). This HP
would serve a vulnerable rural population with limited access to and gaps in care. The health
system would support\ a hospital-based clinic managed by a registered pharmacist (RPh);
this clinic would collaboratively treat HF patients with confirmed ID with IV iron in the
home providing follow up monitoring for 6 months, thus reducing a significant barrier to
treatment for IV iron. The HP would follow an algorithm to screen and to treat patients with
chronic stable HF and ID; chronic HF is defined as current euvolemic status with no
hospitalization in past 3 months. Clinicians in the HP would determine the etiology of ID
and refer to specialists as appropriate. If the patient with HF needs iron replacement, then
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the physician or NP orders oral ferrous sulfate 325 mg daily for 8 weeks. If a patient would
fail to tolerate dosing, to respond by improved symptoms or by target hemoglobin, or TSat <
20%, then the patient could be referred to the hospital clinic for IV iron infusion. However,
if the patient has underlying comorbidities where initial oral iron supplementation is not
appropriate, then the patient could be referred directly to the hospital clinic for home
administration of IV iron (Silverberg et al., 2015).
Theoretical Framework
Quality improvement practices can reduce disparities in health outcomes among
patients with ID and HF who live at home with restricted access to care and to treatment.
Coordinated care can reduce hospitalizations, cost and improve quality of care;
understanding and utilizing current organizational structural characteristics can shape health
system processes to improve outcomes (Lawson & Yazdany, 2012; Liu et al., 2011). Thus,
Donabedian’s model for the assessment of health care quality and improvement utilizing a
structure-process-outcome (SPO) framework will be employed in this project.
There may exist a gap in the process for detecting and treating patients with HF and
ID enrolled in a rural HP. A large Mid-Atlantic health system should have the necessary
organizational infrastructure to design and implement an evidence-based algorithm targeting
vulnerable patients with HF and ID in a home setting using the electronic health record
(EHR) for patient selection criteria with the integration and application of standardized
processes which reflect evidence-based practices that may potentially influence outcomes.
Improvement in care processes must be strongly linked to health outcomes to assure validity
of quality metrics (Lawson & Yazdany, 2011). Retrospective data analysis for this project
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may capture measurable elements of practice performance which can be applied to change
the quality of care for this vulnerable population. Patient-centered outcomes should also be
considered as a meaningful metric given the significant symptom burden of HF in patients
with ID and the potential to influence utilization and prognostication.
Search Strategy
With the assistance of a hospital research librarian, the literature search was
conducted through CINAHL, PubMed and Cochrane Library databases with English-only,
peer-reviewed, full-text articles from January 2010 to September 2021 with the following
keywords, phrases with the Boolean characters AND, OR: systolic, heart failure, iron
deficiency, home, management. The search yielded 290 articles; after excluding acute heart
failure and hospitalization, 40 articles were in European journals, 16 in European
supplements, 11 in Journal of Cardiac Failure, 10 in Circulation, 8 in Heart, Lung and
Circulation and 7 in Journal of the American College of Cardiology. Fifteen were included
for the review. Literature that did not include trials were reviewed, including professional
society guidelines and expert analyses. Manual reference list searches yielded another 7
articles for review.
Critical Appraisal of the Literature
It is important to understand the fundamentals of iron replacement when reviewing
data. Iron deficit is calculated by Ganzoni’s formula published in 1970 and is weight based.
The calculated result is usually 1,000 mg or higher in most cases and IV iron dosages are
usually administered at a dose to replenish iron stores. Small amounts of iron are absorbed
in the gut and up to 40% of patients experience side effects affecting adherence;
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replenishment of iron stores usually takes 2 to 6 months, thus the majority of the early
studies utilized IV iron preparations (von Haehling et al., 2019).
As ID is linked to cardiac function, the past several decades has seen an increasing
interest in the study of anemia and ID in HF patients as prevalence continues to rise. The
first studies in 1990s such as the Reduction of Events by Darbepoetin Alfa in Heart Failure
Trial (RED-HF) clinical trial examined exercise tolerance in patients in Tel Aviv. Using iron
sucrose and subcutaneous erythropoietin, the findings showed no mortality benefit and an
increased rate of serious thromboembolic events using target peripheral hemoglobin > 13
g/dl in patients receiving darbepoetin-alfa than in patients receiving the placebo. After the
published results, the use of erythrocyte-stimulating agents in trials declined (von Haehling
et al., 2019).
Studies with controlled trials continued with varying enrollment, length of duration,
classes of HF, hemoglobin criteria and iron preparation. Several early studies had very low
enrollment. The Effects of Intravenous Iron Sucrose on Exercise Tolerance in Anemic and
Nonanemic Patients with Symptomatic Chronic Heart Failure and Iron Deficiency Study
(FERRIC-HF) with 35 patients used NYHA class II-III patients with EF < 45 % and hgb <
12.5 in the anemic group with iron sucrose given 200mg weekly until ferritin > 500 ng/ml.
Patients completed the study in 16 weeks. Toblli et al. published a randomized control study
in 2007 including 40 patients with EF < 35 % and NYHA class II-IV and hemoglobin <
12.5 g/dl, and the total iron given was 1000 mg of iron sucrose over 5 weeks. Primary
endpoint was change in BNP and inflammatory markers by clinical laboratory testing;
however, larger studies with statistical significance were needed.
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Several studies recruited significant numbers of patients and were later included in
two meta-analyses. The first large-scale, double-blind, placebo-controlled multicenter trial
of ferric carboxymaltose (FCM) in patients with chronic HF, known as Ferinject
Assessment in Patients with Iron Deficiency and Chronic Heart Failure (FAIR-HF) Trial,
was published in 2009; 459 patients with NYHA class II and EF < 40% or class III with
LVEF and EF < 45% with hgb > 9.5 g/dl and < 13.5 g/dl were treated in the correction
phase of ID using 200mg weekly doses followed by a maintenance phase with monthly
FCM doses. Outcomes were improved quality of life and exercise tolerance. These findings
supported the use of IV iron with recommendations to consider FCM for ID in HF patients
in the 2012 European Society of Cardiology guidelines.
The second large-scale trial of FCM in HF patients was known as the Ferric
Carboxymaltose Evaluation on Performance in Patients with Iron Deficiency in
Combination with Chronic Heart Failure Study (CONFIRM-HF) which enrolled 304
patients with similar HF class and EF to those in FAIR-HF trial, with duration of 52 weeks.
Patients received between 500 mg and 2,000 mg of FCM or placebo in first weeks then
received 500mg of FCM in weeks 12, 24, and 36 if ferritin and or TSat still reflected ID.
Outcomes showed increase in 6-minute walking distance from baseline to 24 weeks that was
maintained to week 52.
The first meta-analysis of IV iron use in HF patients was published in the European
Journal of Heart Failure by Jankowska et al. in 2016. This review included 5 clinical studies
with total enrollment of 851 patients, 509 of whom received iron sucrose or FCM. This
analysis showed IV iron was found to reduce the risk of hospitalization for patients with
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HFrEF. The study also supported a reduction in NYHA functional class, increase in 6minute walk test and improved quality of life scores using different assessment tools.
The second meta-analysis was published by Anker et al. in 2018, also in the European
Journal of Heart Failure. Patient data were extracted from 4 random-controlled trials
comparing FCM with placebo in HFrEF patients with ID. This analysis of 839 patients, of
whom 504 were randomized to FCM, showed patients on FCM had lower rates of recurrent
cardiovascular hospitalizations and cardiovascular mortality which suggested the beneficial
effects of IV iron treatment in HF patients. This analysis led the development of the
prospective FAIR-HF II trial which is ongoing with target enrollment of 1,200 HF patients.
Recommendation by the ACC to consider IV iron replacement in patients with
NYHA class II and III with ID to improve functional status and quality of life was included
in 2017 updated guidelines with level IIb evidence (Yancy et al., 2017). The ACC does not
mention a certain IV iron preparation but the European guidelines advocate only for the use
of FCM. It is noted that the same manufacturer of FCM sponsored the FAIR-HF and
CONFIRM-HF trials (Ghafourian et al, 2020). Currently, ACC guidelines in 2021 support
the administration of IV iron for symptom improvement in patients with HFrEF and ID
(Maddox et al, 2021). Thus, it is important to include patient assessment in the treatment of
ID.
Studies of oral iron use in HF patients with ID are very limited. This may represent
funding and recruitment issues. The first oral iron study was in 2013, known as Short Term
Oral Iron Supplementation in Systolic Heart Failure Patients Suffering from Iron Deficiency
Anemia (IRON 5), that randomized patients to one of three groups: one was given oral
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ferrous sulfate therapy and one was given IV iron sucrose or placebo; oral iron was given
for 8 weeks and IV iron over 5 weeks. The study ended early with only 23 patients in the
database. The second trial with oral iron was between 2014-2015 in 23 US sites, known as
the Oral Iron Repletion Effects on Oxygen Uptake in Heart Failure (IRONOUT HF) study,
of 225 randomized HF patients with EF < 40% with ID who were given oral iron
polysaccharide 150mg twice a day over 16 weeks with no significant increase in peak
oxygen uptake or improved 6-minute walk test. Although mildly increased serum ferritin
and TSat levels were noted, those findings were not considered sufficient to recommend oral
dosing in ID treatment (Lewis et al., 2017).
Research gaps
Additional studies are being designed and conducted to evaluate the benefits of
different iron preparations and in different HF types. It is not known if HF patients with
HFpEF respond to IV iron with similar findings in HFrEF patients. In review of the current
studies, there is a wide variation of EF criteria, hgb measurements, BNP collection, duration
of study, and dosages of iron (McDonagh, 2016).
In the recent expert analysis of anemia and HF by Silver and Anker (2021), the
authors acknowledge the need for a stronger definition of anemia and ID in HF and better
measurement of ID with ongoing efforts to detect and to treat ID. Patients with HF are not
being identified and targeted for treatment which has far-reaching implications. Thus,
efforts to reduce current gaps in awareness of anemia prevalence in HF must be a priority in
practice.

As researchers continue to look for best evidence, utilization of the current HF

guidelines will continue to inform practice and to improve awareness and care. However,
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we must be certain to include measurement of patient-related outcomes such as life quality
and days out of the hospital. These health system metrics are needed to accurately capture
meaningful data.
It is vitally important to document patient outcomes, especially if those outcomes are
targets of treatment. The quality-of-life parameters of each HF tool were not fully explored
in the studies. The majority of studies utilized several assessment tools but the full
explanation of response variations was not reviewed. Several tools were mentioned such as
the Kansas City Cardiomyopathy Questionnaire, Patient Global Assessment, and Minnesota
Living with Heart Failure Questionnaire, all of which are validated and useful tools to assess
HF symptom burden and quality of life measures. More research is needed to understand
how to integrate these tools into clinical practice and to assess the impact on patient care
(Spertus et al, 2015; Yee et al., 2019).
Purpose of Project
There is a need to explore the scope of undetected and untreated patients with HF and
ID in the rural home setting (Silver & Anker, 2021). Untreated ID impacts patient quality of
life experiences and can worsen disease burden. This project will examine the screening and
treatment process of patients with HF and comorbid ID. It will be limited to those currently
enrolled in a rural HP who are agreeable to take iron supplements and to utilize home
phlebotomy for standardized blood work collection. The findings will be described by a
retrospective analysis to understand trends in demographics, HF class, referrals to hospital
clinic, and health care utilization with practice implications and recommendations.
Donabedian’s model is a natural fit for this quality improvement project. There is
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generally strong infrastructure within a large health system to support the process
development of a refined algorithm. The oral and IV iron would be covered by patient
insurance; IV iron could be ordered and administered at home by a hospital clinic
pharmacist in contact with HP providers, greatly reducing a well-known barrier to access.
This project could lead to a best-practice protocol to formalize detection, screening and
treatment of HF patients with ID to improve system and practice awareness and outcomes.
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Chapter 3
Methodology
Quality Improvement Framework
Donabedian’s theoretical framework for quality improvement (QI) initiatives will be
applied for this project, using the SPO approach. The aim of this QI project is to analyze the
process by which patients with HF and ID are identified and treated using an algorithm with
current best-practices to shape outcomes. In this project, the structure is well-established by
institutional support; thus, the process, if correctly implemented, should lead to a positive
outcome, such as target hemoglobin and best practice advice in the electronic health record
for patients enrolled in home-based program.
Many patients have a diagnosis of HF which is leading cause of hospital admissions,
emergency room utilization, and reduced quality of life. An institution-supported program
would provide the structure for this project; there is generally strong emphasis on innovation
in large health systems to utilize current evidence to inform practice. A multi-disciplinary,
home-based program for patients enrolled with serious and chronic illnesses is an ideal
setting with the goal to improve access to services and to reduce utilization.
Setting
This QI project will focus on patients enrolled in a rural mid-Atlantic HP from
August 2021 through March 2022. The HP covers several counties where access to care
may be limited and health literacy may be low. The HP employs a multi-disciplinary team
of medical providers, nursing staff, social workers, and dietician.
This QI project is supported by the health system administration, HP leadership and
the regional clinicians; site support for this project will be obtained by the HP medical
17

director and health system nursing research council (see Appendix A). The medical director
is responsible for the QI project workflow design and implementation in collaboration with
the hospital-based clinic. Working closely with the information technology (IT) team for the
health system, the HP project clinical team is assisted with data support including patient
identification in the EHR and clinical indicators. The health system uses a biomedical
statistician for data analysis who would be recruited for this project to assure data accuracy
and patient confidentiality.
For this project, several hundred patients would be eligible with a diagnosis of HF;
however, a much smaller number have defined anemia. The cost of this project for staffing
will be supported by the HP administration, and patient medication and blood work are
covered by health insurance. Mobile phlebotomy would be utilized for access to patients at
home and for consistency in laboratory reporting. Home infusion of IV iron would also be
covered by insurance and supported by the health system infrastructure.
Sample
Prior to August 2021, identified patients with HF and ID were treated by the hospital
clinic utilizing their evidence-based algorithm; after which time, the HP medical director
worked with health system IT to identify patients with HF in all covered counties of the HP
who did not have a CBC in the past year and were also identified to be iron deficient by
blood testing. Following an algorithm, patients to be included for this project must be over
the age of 18 years with an established diagnosis of HF in chronic, not acute or
decompensated, condition with anemia and iron deficiency. All patients must have health
insurance. Patients to be excluded are those with an active malignancy or other comorbid
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conditions, such as kidney failure, which put them in an unstable, high-risk category for
urgent referral or specialist treatment. Also, patients may refuse to accept oral or IV iron.
Ethical Considerations
Informed consent will not be required as these patients are participating in a QI
project and not research. On November 1, 2021, the Institutional Review Board (IRB) of the
health system approved this project for QI (see Appendix B). All patients who meet criteria
will be offered treatment or referral, as indicated. To protect patient data in the EHR, only
project participants will have secure access to patient data related to the project and data will
be de-identified during collection for statistical purposes; all laboratory testing and clinical
notes in the EHR will be available to all pertinent parties related to patient care. After data
collection, analysis and project completion, all de-identified data logs will be destroyed
according to institutional and federal guidelines.
Methods
Patients are identified by the HP algorithm. The HP approach differs from the
hospital clinic algorithm in that all HF patients are included, not only patients with HFrEF,
who are usually included in clinical trials and targeted in guidelines. However, more
research is needed. Thus, those patients with all types of HF, with anemia and defined iron
deficiency, would be offered oral iron sulfate 325mg daily for 8 weeks, after discussion
between the individual clinician and the patient for the most appropriate and patientcentered care. Some patients might receive IV iron if it is determined to be the most
appropriate treatment. Patients would be discharged from treatment when target hemoglobin
is reached by blood analysis.
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Data collection
After obtaining a student organizational contract, data are reviewed retrospectively to
analyze the effect of the process to identify, screen and treat patients with HF and ID at
home with oral or IV iron to target hemoglobin. Data will be obtained from the EHR by the
project medical director and select support staff, minimizing the risk of error in
computation. Data will be reviewed for completeness. There is no tool to score. Data will be
secured in a desktop computer and locked office accessible only by project staff. West
Chester University Institutional Review Board submission and acceptance will be secured
(see Appendix C).
Data Analysis
To analyze the results, the data will be de-identified and entered in an Excel
spreadsheet. Descriptive statistics will be analyzed with the assistance and supervision of a
biostatistician who is employed by the organization or by statisticians in training under
supervision. Dissemination of findings will be presented to the organization and to West
Chester University faculty after securing a student contract. Practice implications and
recommendations for improvement and for future nursing research will be detailed.
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Chapter 4
Results
Data Collection
The results of data collection and analysis for this quality improvement project were
planned by a retrospective analysis of demographics, clinical data and utilization markers
over 8 months to show the effect of a process to influence outcomes in patients enrolled in a
rural home program with HF and ID. All patients were diagnosed with HF, and the majority
of target populations met criteria for anemia with the exception of patients with no blood
work in past year. The HP medical director, HP pharmacist and advanced practice providers
were responsible for ordering and interpreting blood work, ordering oral iron, placing
referrals to the anemia clinic or other specialists, and for follow up.
The medical director and clinical team met regularly to discuss the current monthly
findings, to review progress and to address issues. It became clear that a more refined
anemia algorithm was needed and a health system-employed hematologist was consulted for
project discussion, specifically to define which patients should not receive iron and when a
referral to hematology was needed. This refined algorithm is being developed.
For the quality improvement project, the data points included sex, hemoglobin
measurement, treatment with oral iron, referrals to hospital clinic for IV iron, length of
treatment and health system utilization. The health system supported the analysis by
collaborating with an information technologist and statistician employed by the organization
but who were not involved in daily project oversight. Anticipated process outcomes were
favorable to support the use of this algorithm to identify and treat patients in the home
program.
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Data Analysis
This project was initially supported by the organization and by the HP leadership;
however, data analysis was not completed as anticipated due to a student contract impasse
which prevented the computation, analysis, and reporting of organizational data. The HP
medical director for the QI project will review data and present to the organization which
may lead to a research project. In follow up, an institutional review board application may
be submitted to evaluate the outcomes further in a formal cohort study.
This project could also lead to an EHR-supported best practice advice for clinicians
treating HF patients enrolled in the HP to ensure patients are properly identified, screened
and treated for ID at least on an annual basis which can be measured. Additionally, a
patient-centered symptom assessment tool for HF patients could also be utilized to assess
the effect of ID-related symptom burden in patients at home. This tool could also be shared
with the outpatient cardiology teams for deployment and system-wide outcomes
measurement.

22

Chapter 5
Discussion
Review
Heart failure is a common diagnosis with high morbidity in the U.S. and professional
organizations have developed guidelines to target therapeutics. Outcomes, both patientcentered and organizational, are affected. To reduce hospital readmissions related to HF,
organizations across the US are tasked with investigating novel approaches to care.
As HF is linked to underlying systemic inflammation, certain comorbid diagnoses
have the potential to impact the disease trajectory. Anemia with iron deficiency can worsen
symptom burden and clinical outcomes in patients with HF yet ID continues to be underrecognized and under-treated. It is not known how often a patient should be assessed for ID.
Clinical trials are ongoing to determine best evidence; the majority of trials targeted patients
with HFrEF and utilized IV iron which may not always be practical or available to the
community at-large. However, trials with oral iron were limited in number and enrollment.
Thus, rural homebound patients may be even further limited in treatment options; it is
imperative to identify and to treat those at risk to improve outcomes and quality of life,
especially in vulnerable populations who lack access to care and to treatment.
Findings
This project is supported by Donabedian’s SPO framework and outcomes should
reflect the validity of the structure and process being applied. The setting within this
organization with rural home-based patients and the use of a clinical algorithm from late
2021 should have led to outcomes which supported identification and screening for ID in
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patients with HF. However, the process could not be fully assessed by descriptive data as
planned due to a student contract impasse. It is known that HF patients in a rural HP were
identified as being anemic and iron deficient. In application of the algorithm, appropriate
patients were evaluated. Full treatment with iron takes several months for repletion.
The most recent literature findings and clinical guidelines support repletion of iron in
HF patients with ID for symptom management. There is limited evidence for oral iron in ID
with HF but studies are ongoing. It is not known how many patients were successfully
treated with oral iron and for which types of HF and how many were referred to the hospital
clinic to arrange IV iron at home. Yet, patients were identified for screening; this project
may demonstrate the need for an algorithm to consistently identify those vulnerable patients
who may miss routine screening of and treatment for ID.
Implications for Practice, Education and Policy
This clinical algorithm could be important for HP clinicians to have a process by
which to identify at-risk patients; the development of a best practice alert in the EHR could
prompt a clinician to order routine blood work at least annually for any patient with HF who
has not had blood work in past year to identify anemia, after which the algorithm could be
followed for ID treatment. Patient education can be tailored to treatment adherence and to
reporting of side effects, a frequent cause of treatment failure with oral iron. Home program
nurses involved in patient care could make weekly phone calls to assess for side effects and
the HP pharmacist can track adherence also by monthly refills, if covered by insurance and
not purchased out of pocket.
Worsening HF symptoms are important for assessment and for treatment. Patients
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must also be aware of worrisome symptoms to report for ID to be detected. Patient
education with an evidence-based HF tool such as the Kansas City Cardiomyopathy
Questionnaire (KCCM) can empower patients to self-report and may be helpful to employ in
the home setting and in HF clinics for data measurement. However, it would need to be
approved by the health system and employed HF specialists before system-wide
deployment; IT could link it to the EHR for data tracking. Nurses and CHW could introduce
the KCCM at home for completion and to answer questions in person and later follow up
with a 6-minute walking test every month to assess exercise tolerance with ID. The KCCM
could be added to each clinical progress note with findings that can be retrieved later in the
EHR for outcomes measurement; furthermore, the HP staff and outpatient palliative care
and HF teams can draft a policy to use the KCCM for symptom burden and quality of life
assessment with all HF patients, adding to health system outcomes data.
Future Research
A prospective cohort study with a similar HF population for comparison would be
necessary to study the impact of identification and treatment of ID for statistical
significance. Clinical trials in the U.S. are ongoing to determine which types of HF respond
to treatment and the clinical significance of treatments. It is not known how frequently
patients with HF should be assessed for ID and which treatments should be offered for
clinical benefit. More research is needed in patient-centered care with HF treatment and in
utilization of evidence-based HF assessment tools for outcomes measurements.
Limitations
Only active patients from the HP over several months were included in this project.

25

Patients from a rural area in the mid-Atlantic region may not be representative of HF
patients with ID in other rural areas of U.S. The HF patients in this project had the unique
support and infrastructure of a multi-disciplinary HP and a hospital-based clinic through
which to administer IV iron at home that may not be available or possible in other U.S.
regions.
Conclusion
Although this quality improvement project was not completed through data analysis,
the anticipated outcomes of this project reinforce the importance of a standardized process
by which rural HF patients in a home setting are identified for anemia then screened and
treated for ID to reduce utilization and to reach target clinical goals. It is based on a
validated SPO framework. This is an important project to consider for advanced practice
clinicians who serve in rural areas to reduce poor outcomes by impacting disease
progression and for researchers to add to the clinical body of knowledge to improve care
and outcomes. It brings awareness to an area of under-detection that has far-reaching
implications for health systems and patient-centered outcomes. Nurses continue to play a
pivotal role in reducing disparities, improving care trends, and advancing health.
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